Cover Image
市場調查報告書

Biodel Inc.的產品平台分析

Biodel Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253712
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Biodel Inc.的產品平台分析 Biodel Inc. - Product Pipeline Review - 2015
出版日期: 2015年02月28日 內容資訊: 英文 39 Pages
簡介

Biodel Inc.是總公司在美國的生物製藥企業,著重糖尿病治療的創新醫藥品候補物質的開發及商品化。以強化現行藥物的藥效的製劑技術為基礎,進行產品開發。

本報告提供Biodel Inc. 的治療藥開發平台的現狀及各開發階段比較分析,各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Biodel Inc. 的基本資料

  • Biodel Inc. 概要
  • 主要資訊
  • 企業資料

Biodel Inc. :R&D概要

  • 主要的治療範圍

Biodel Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Biodel Inc. :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的開發中產品/聯合治療模式
    • 第一階段的開發中產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Biodel Inc. :藥物簡介

  • BIOD-123
  • BIOD-531
  • BIOD-125
  • BIOD-238
  • BIOD-250
  • glucagon
  • VIAtab
  • BIOD-530
  • teriparatide
  • VIAcal

Biodel Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Biodel Inc. :最近的開發平台資訊

Biodel Inc. :開發休止的計劃

Biodel Inc. :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • BIOD-105
    • BIOD-107
    • Linjeta

Biodel Inc. :企業理念

Biodel Inc. :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06829CDB

Summary

Global Markets Direct's, 'Biodel Inc. - Product Pipeline Review - 2015', provides an overview of the Biodel Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biodel Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biodel Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biodel Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biodel Inc.'s pipeline products

Reasons to buy

  • Evaluate Biodel Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biodel Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biodel Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biodel Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biodel Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biodel Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biodel Inc. Snapshot
    • Biodel Inc. Overview
    • Key Information
    • Key Facts
  • Biodel Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Biodel Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Biodel Inc. - Pipeline Products Glance
    • Biodel Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Biodel Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biodel Inc. - Drug Profiles
    • BIOD-123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIOD-531
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIOD-125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIOD-238
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIOD-250
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glucagon
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VIAtab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BIOD-530
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • teriparatide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VIAcal
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biodel Inc. - Pipeline Analysis
    • Biodel Inc. - Pipeline Products by Target
    • Biodel Inc. - Pipeline Products by Route of Administration
    • Biodel Inc. - Pipeline Products by Molecule Type
    • Biodel Inc. - Pipeline Products by Mechanism of Action
  • Biodel Inc. - Recent Pipeline Updates
  • Biodel Inc. - Dormant Projects
  • Biodel Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • BIOD-105
      • BIOD-107
      • Linjeta
  • Biodel Inc. - Company Statement
  • Biodel Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biodel Inc., Key Information
  • Biodel Inc., Key Facts
  • Biodel Inc. - Pipeline by Indication, 2015
  • Biodel Inc. - Pipeline by Stage of Development, 2015
  • Biodel Inc. - Monotherapy Products in Pipeline, 2015
  • Biodel Inc. - Phase II, 2015
  • Biodel Inc. - Phase I, 2015
  • Biodel Inc. - Preclinical, 2015
  • Biodel Inc. - Pipeline by Target, 2015
  • Biodel Inc. - Pipeline by Route of Administration, 2015
  • Biodel Inc. - Pipeline by Molecule Type, 2015
  • Biodel Inc. - Pipeline Products by Mechanism of Action, 2015
  • Biodel Inc. - Recent Pipeline Updates, 2015
  • Biodel Inc. - Dormant Developmental Projects,2015
  • Biodel Inc. - Discontinued Pipeline Products, 2015
  • Biodel Inc., Other Locations
  • Biodel Inc., Subsidiaries

List of Figures

  • Biodel Inc. - Pipeline by Top 10 Indication, 2015
  • Biodel Inc. - Pipeline by Stage of Development, 2015
  • Biodel Inc. - Monotherapy Products in Pipeline, 2015
  • Biodel Inc. - Pipeline by Top 10 Target, 2015
  • Biodel Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Biodel Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Biodel Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top